Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

NCT ID: NCT05908240

Last Updated: 2025-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

520 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-15

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Psoriatic Arthritis Psoriatic Conditions Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Care Coordination

Group Type OTHER

Care Coordinator Model

Intervention Type OTHER

A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Care Coordinator Model

A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing and able to provide informed consent
2. Male or female aged 40-75
3. Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis

Exclusion Criteria

1. Currently taking a prescription lipid lowering medication
2. Pregnant or planning pregnancy in the next 6 months
3. Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Psoriasis Foundation

OTHER

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johnson Dermatology

Fort Smith, Arkansas, United States

Site Status RECRUITING

Dawes Fretzin Clinical Research

Columbus, Indiana, United States

Site Status RECRUITING

Dawes Fretzin Clinical Research

Indianapolis, Indiana, United States

Site Status RECRUITING

MiSkinCenter

Northville, Michigan, United States

Site Status RECRUITING

SUNY Downstate

Brooklyn, New York, United States

Site Status RECRUITING

City Dermatology

Bensalem, Pennsylvania, United States

Site Status RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

University of Utah

Salt Lake City, Utah, United States

Site Status RECRUITING

University of Virginia

Charlottesville, Virginia, United States

Site Status RECRUITING

Bellevue Dermatology Clinic

Bellevue, Washington, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brooke Bishop, MPH

Role: CONTACT

267-581-9714

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karen Garduza

Role: primary

Betty Uyesugi

Role: primary

Ashley Wallace

Role: primary

Jamie Szkodzinski

Role: primary

Tristi Edwards

Role: primary

Arslan Amir

Role: primary

Brooke Bishop, MPH

Role: primary

267-581-9714

Isaac Goddard

Role: primary

Lauren Khuns

Role: primary

Emily Leung

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

853218

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Psoriatic Arthritis D2P Screening
NCT04110522 RECRUITING NA
Psoriasis Longitudinal Assessment and Registry
NCT00508547 ACTIVE_NOT_RECRUITING